These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The surgical team used LD Flap Reconstruction, a specialised technique that rebuilt elbow strength and movement
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
